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Induced pluripotent stem (iPS) cells are generated by epigenetic 
reprogramming of somatic cells through the exogenous expression of 
transcription factors. Recently, the generation of iPS cells from patients 
with a variety of genetic diseases was found to likely have a major 
impact on regenerative medicine, because these cells self-renew 
indefinitely in culture while retaining the capacity to differentiate into 
any cell type in the body, thereby enabling disease investigation and 
drug development. This review focuses on the current state of iPS cell 
technology and discusses the potential applications of these cells for 
disease modeling; drug discovery; and eventually, cell replacement 
therapy.
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Introduction
Since their first isolation, embryonic stem (ES) cells have been 
regarded as the gold standard for potential use in cell-based 
regenerative medicine. The pluripotent nature of these cells provides 
them with, the ability to self-renew indefinitely in culture while 
retaining the capacity to differentiate into any cell type in the body
1). 
However, the fact that ES cells can only be derived from early-stage 
embryos precludes the establishment of autologous cell lines for 
patients and immune rejection hinders the use of nonautologous ES 
cell lines
2).
The advent of mammalian somatic cell nuclear transfer (SCNT) 
first appeared to offer solutions for overcoming these roadblocks. 
SCNT is a technique whereby the DNA of an unfertilized egg 
is replaced by the DNA of a somatic cell. Although significant 
advancements toward this goal have been made, successful 
SCNT into human cells remains an elusive goal and is fraught 
with social and logistical concerns
3). Alternative methods for 
deriving pluripotent cells, such as cell fusion and culture-induced 
reprogramming, have been developed, but these approaches still 
suffer from severe practical and technical limitations
4).
In 2006, Takahashi
5) and Yamanaka reported the astonishing 
discovery that somatic cells could be reprogrammed to adopt the 
pluripotent stem cell state. The generation of pluripotent cells by 
exogenous expression of transcription factors circumvents many 
previous limitations because this approach is not technically 
demanding and does not require embryonic material or oocytes. 
We therefore believe that this discovery which is now known 
as “induced pluripotent stem cell technology” (iPS) will have a 
significant impact on regenerative medicine. In this article we 
review the current methodologies used for generating iPS cells and 
then discuss their potential clinical applications.
Reprogramming somatic cells towards pluripotency 
by defined transcription factors
5)
To establish the transcription factors necessary for repro-
gramming of differentiated cells, mouse embryonic fibroblasts 
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and tail-tip fi  broblasts of mice were initially used. Reprogrammed 
somatic cells were identified by selecting for the reactivation of 
the Fbx-15 gene locus with a neomycin-reporter cassette whose 
expression is restricted to the early stage of embryonal development. 
Cells which are only resistant to G418 selection allowed growth of 
ES-cell-like colonies and cells derived by sub-culturing these ES-
like colonies were designated as “induced pluripotent stem cells.” 
It was found that of the 24 candidate genes that are implicated 
in the establishment and maintenance of the pluripotent state, 
Oct4 (Pou5f1), Sox2, c-Myc, and Klf4, were sufficient to mediate 
reprogramming. These iPS cells had fully demethylated Oct4 
and Nanog promoters and could contribute to the formation of 
germline-competent chimeras upon injection of blastocysts, a 
characteristic which demonstrates true pluripotency.
Preferred methods for preparation of iPS cells
First-generation iPS cells were generated by retroviral trans-
duction
5). Since then, the technique has been optimized and 
reproduced in a number of diff  erent processes
6). Several important 
variables include the choice of cell type for reprogramming, the 
choice of the combination of genes and small molecules used for 
reprogramming, as well as the gene transfer method (Fig. 1). 
For the fi  rst reprogramming attempts of both mouse and human 
cells, fi  broblasts were used as the starting cell population
5). Since the 
original success of fibroblast reprogramming, multiple cell types 
have been used for reprogramming, including keratinocytes, neural 
progenitor cells, hepatocytes, stomach epithelial cells, pancreatic 
beta cells and intestinal epithelial cells
7). Several factors must 
therefore be considered in determining the optimal cell type for a 
given application: (1) the ease with which reprogramming factors 
can be introduced, which varies according to cell type and delivery 
approach; (2) the availability and ease of derivation of the given 
cell type; and (3) the age and source of the cells used
6). An inverse 
correlation has been eff  ectively demonstrated for the diff  erentiation 
stage of target cells. For example, with mouse hematopoietic stem 
and progenitor cells being more efficiently reprogrammed than 
terminally diff  erentiated B and T lymphocytes
8, 9). While fi  broblasts 
are likely to remain the choice cell type in basic research eff  orts, iPS 
cells derived for therapeutic purposes will require the donor cells to 
be easily attainable, less likely to contain genetic aberrations, and 
easy to reprogram using transient approaches
6).
Since the first report of reprogramming, it has become evident 
that there is some flexibility in the factors needed to reprogram 
somatic cells. Of the original four transcription factor-encoding 
genes, c-Myc is not strictly required for the reprogramming of 
somatic cells and Klf4 and Sox2 have been shown to be dispensable 
in reprogramming strategies utilizing cell types that endogenously 
express them. Oct4 is the only factor that cannot be replaced by 
other family members and the only one that has been required in 
every reprogramming strategy in either mouse or human cells
8).
To aid in the production of epigenetic modifications during 
the reprogramming process, several studies have examined 
the use of small-molecule compounds. Importantly, small 
molecules, including DNA methyltransferase inhibitors
10), the 
histone deacetylase inhibitor valproic acid
11), and the histone 
methyltransferase inhibitor BIX-0 1294
12),
 have been shown to 
substantially improve the efficiency of reprogramming, even in 
cases without inclusion of exogenous Klf4 and c-Myc (for valproate) 
or exogenous Sox2 and c-Myc (for BIX-01294). In addition, 
inhibition of DNA methyltransferase activity by 5-aza-cytidine 
also was found to improve reprogramming efficiency
13). Recently, 
another small molecule, transforming growth factor RI kinase 
inhibitor II, has also been reported to replace Sox2 by the induction 
of Nanog
14).
 Of note, the effects of these small-molecule agents 
are not directed towards specific reprogramming events, and it 
remains to be determined whether full reprogramming through the 
exclusive use of chemicals is possible.
iPS cells have been generated using a number of different gene 
transfer methods, including retroviral, lentiviral, and adenoviral 
vectors and nonviral plasmids, and recently by direct recombinant 
protein delivery
8). Initial generations of mouse and human iPS 
cells employed retroviral vectors
5) and constitutive lentiviruses
15).
Th   ese viral systems, however, have been criticized because they are 
permanently integrated into the genome and endeavors to make 
iPS cells more therapeutically applicable have led to the pursuit of 
non-integrative approaches. A refined system which employs the 
Crelox system or transposases in which reprogramming factors 
could be delivered into the host genome and removed without any  Fig. 1. Overview of the processes for inducing the derivation of 
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residual elements has been recently developed
16). More importantly, 
iPS cell generation has now been achieved without genomic 
integration. This has been accomplished using adenoviruses
17), 
repeated plasmid transfection
18), and recombinant proteins
19) 
and via the use of episomal vectors
20) in human cells. However, 
the reprogramming efficiency obtained using these delivery 
systems tends to be dramatically lower for most cell types relative 
to the standard retroviral/lentiviral mediated reprogramming
7). 
Ultimately, the logistical, financial, and practical aspects of each 
technique must be taken into account. It is likely that the optimal 
cell reprogramming method will be determined by the intended 
application of the reprogrammed cells. Currently, for example, the 
fastest and most efficient method of creating human iPS cell lines 
through lentiviral and retroviral transduction might represent the 
preferred approaches for generating iPS cells for use in large-scale 
drug-screening programs and disease modeling
8).
Clinical relevance
The recent introduction of iPS cell technology has opened a 
new avenue not only for cell replacement therapy but also for 
disease modeling and drug development
21). The generation of 
human iPS cells from patients with a variety of genetic diseases 
with either Mendelian or complex inheritance including X-linked 
adrenoleukodystrophy (X-ALD), amyotrophic lateral sclerosis, 
Duchenne and Becker muscular dystrophy, Parkinson’s disease, 
Huntington’s disease, Gaucher disease type III, and Down 
syndrome is also possible. Such disease-specific iPS cells offer 
an unprecedented opportunity to recapitulate both normal and 
pathologic human tissue formation in vitro, thereby enabling 
disease investigation, drug development and cell therapy
21).
Conclusion
As a result of its tremendous potential in a wide variety of 
clinical and research applications, there is great interest in cellular 
reprogramming. The recent successes in iPS cell derivation without 
the use of viral vectors and genomic integration from human cells 
has brought the realization of the therapeutic potential of iPS cell 
technology closer than ever. Importantly, however, there is still 
much to learn about how this reprogramming process works. 
The key steps involved in this process consist of the choice of 
reprogramming factors and molecules, their delivery method, and 
the choice of target cell type. Given the high level of interest in iPS 
cells and the large number of laboratories around the world that are 
now studying these cells, we are hopeful that iPS cell technology 
will have a positive impact on therapeutic interventions.
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